



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 - E-mail: info@pharmacy.la.gov



BULLETIN No. 26-01

To: All Pharmacies, Pharmacists, Pharmacy Interns, Pharmacy Technicians, and Pharmacy Technician Candidates

From: Joe Fontenot, Executive Director

Date: July 10, 2026

Re: Legislative Update: 2026 Regular Session

During its 2026 Regular Session, the Louisiana Legislature passed new laws that impact pharmacy practice and the Board's operations. While most of these laws take effect on August 1, 2026, a few have other effective dates. A brief noncomprehensive summary of selected Acts is provided below, with links to the full text:

[Act 58](#) (HB152), effective August 1, 2026, adds certain substances to the Uniform Controlled Dangerous Substances Law. Thirteen substances were added to Schedule I - Opiates.

[Act 183](#) (HB907), effective May 15, 2026, provides for civil and criminal immunity for the distribution or use of opioid antagonists beyond their shelf-life end dates and prohibits disciplinary actions by professional licensing boards for healthcare professionals granted civil and criminal immunity, all of which under certain conditions.

[Act 374](#) (SB253), effective August 1, 2026, provides that no licensing board shall prohibit a Louisiana licensed pharmacist in a state permitted pharmacy from compounding and dispensing peptides if the pharmacist complies with 21 USC 353a (503A) and applicable USP-NF chapters. There is also a provision that no licensing board shall prohibit a healthcare provider with prescriptive authority from providing patients with peptides shipped from either a compliant 503A compounding pharmacy or a compliant FDA-registered 503B outsourcing facility.

[Act 557](#) (HB557), effective August 1, 2026, adds Part VIII to the Pharmacy Practice Act to define long-term care pharmacy. Aligns state law with federal law to clearly identify long-term care pharmacies.

[Act 567](#) (HB779), effective August 1, 2026, adds trichomoniasis and other sexually associated infections determined by the Louisiana Department of Health, to eligible medical conditions for expedited partner therapy.

[Act 649](#) (HB475), effective August 1, 2026, requires a healthcare professional to verbally disclose the use of any recording device, software, or service to a patient before recording any part of an appointment or treatment to be transcribed by artificial intelligence.

Other Acts of Interest:

[Act 770](#) (SB465), effective January 1, 2027, Title 22. Insurance Code - provides for payments and other related matters.

[Act 833](#) (HB766), effective August 1, 2026, Title 22. Insurance Code - provides relative to coverage for orally administered anti-cancer medications.

[Act 907](#) (HB870), effective August 1, 2026, Title 22. Insurance Code - provides relative to formulary placement and cost-sharing requirements for certain generic drugs and biosimilars, and other related matters.

[Act 913](#) (HB1236), effective June 12, 2026, Title 22. Insurance Code - provides relative to PBM reimbursements.

[Act 914](#) (SB387) (various effective dates), Title 22. Insurance Code - provides relative to PBMs.